medRxivGenetic & Genomic MedicinePreprint
A 6-mRNA host response whole-blood classifier trained using patients with non-COVID-19 viral infections accurately predicts severity of COVID-19
Ljubomir J. ButurovićiD, Hong ZhengiD, Benjamin M. P. TangiD, Kevin Lai, Win Sen KuaniD, Mark GillettiD, Rahul Santram, Maryam ShojaeiiD, Raquel AlmansaiD, Jose Ángel Nieto, Sonsoles Muñoz, Carmen Herrero, Nikolaos AntonakosiD, Panayiotis Koufargyris, Marina Kontogiorgi, Georgia DamorakiiD, Oliver LiesenfeldiD, James W. WackeriD, Uros Midic, Roland LuethyiD, David Rawling, Melissa RemmeliD, Sabrina Coyle, Yiran E. LiuiD, Aditya RaoiD, , Timothy E. SweeneyiD
Abstract
BackgroundDetermining the severity of COVID-19 remains an unmet medical need. Our objective was to develop a blood-based host-gene-expression classifier for the severity of viral infections and validate it in independent data, including COVID-19. MethodsWe developed the classifier for the severity of viral infections and validated it in multiple viral infection settings including COVID-19. We used training data (N=705) from 21 retrospective transcriptomic clinical studies of influenza and other viral illnesses looking at a preselected panel of host immune response messenger RNAs. ResultsWe selected 6 host RNAs and trained logistic regression classifier with a cross-validation area under curve of 0.90 for predicting 30-day mortality in viral illnesses. Next, in 1,417 samples across 21 independent retrospective cohorts the locked 6-RNA classifier had an area under curve of 0.91 for discriminating patients with severe vs. non-severe infection. Next, in independent cohorts of prospectively (N=97) and retrospectively (N=100) enrolled patients with confirmed COVID-19, the classifier had an area under curve of 0.89 and 0.87, respectively, for identifying patients with severe respiratory failure or 30-day mortality. Finally, we developed a loop-mediated isothermal gene expression assay for the 6-messenger-RNA panel to facilitate implementation as a rapid assay. ConclusionsWith further study, the classifier could assist in the risk assessment of COVID-19 and other acute viral infections patients to determine severity and level of care, thereby improving patient management and reducing healthcare burden.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Gene Expression Risk Scores for COVID-19 Illness Severity
Derick R. Peterson, Andrea M Baran, … Thomas J. Mariani·The Journal of Infectious DiseasesPeer-reviewed·Nov 29, 2021
- Classification of patients with COVID-19 by blood RNA endotype: A prospective cohort study
Jumpei Yoshimura, Yuki Togami, … Hiroshi Ogura·Microbiology SpectrumPeer-reviewed·Nov 15, 2023
- Genomic Biomarker Heterogeneities Between SARS-CoV-2 and COVID-19
Zhengjun Zhang·VaccinesPeer-reviewed·Oct 2, 2022
- Airway Gene-Expression Classifiers for Respiratory Syncytial Virus (RSV) Disease Severity in Infants
- Elevated anti-SARS-CoV-2 antibodies and IL-6, IL-8, MIP-1β, early predictors of severe COVID-19.
H. Codina, I. Vieitez, … E. Poveda·bioRxiv·Apr 13, 2021
- Dynamic gene expression analysis reveals distinct severity phases of immune and cellular dysregulation in COVID-19
A. An, A. Baghela, … R. E. W. Hancock·bioRxiv·Nov 4, 2023